US2086186A
(en)
|
1933-10-10 |
1937-07-06 |
Us Rubber Co |
Treatment of rubber
|
SU50906A1
(ru)
|
1935-12-20 |
1936-11-30 |
А.И. Бурляев |
Веретено дл пр дильных машин
|
GB1435721A
(en)
|
1972-05-18 |
1976-05-12 |
Lilly Industries Ltd |
Benzoxazole derivatives
|
JPS6192592A
(ja)
|
1984-10-12 |
1986-05-10 |
Norin Suisansyo Shokuhin Sogo Kenkyusho |
分岐サイクロデキストリンの製造方法
|
US4675332A
(en)
|
1984-12-10 |
1987-06-23 |
Warner-Lambert Company |
Acidic tetrazolyl substituted indole compounds and their use as antiallergy agents
|
GB8610981D0
(en)
|
1986-05-06 |
1986-06-11 |
Ici America Inc |
Quinoline amides
|
NZ225045A
(en)
|
1987-07-01 |
1990-06-26 |
Janssen Pharmaceutica Nv |
Antiviral pharmaceutical compositions containing cyclodextrin and an antiviral agent
|
US5002935A
(en)
|
1987-12-30 |
1991-03-26 |
University Of Florida |
Improvements in redox systems for brain-targeted drug delivery
|
US5376645A
(en)
|
1990-01-23 |
1994-12-27 |
University Of Kansas |
Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
|
BR9106193A
(pt)
|
1990-10-22 |
1993-03-23 |
Bausch & Lomb |
Metodo e composicao para limpar lentes de contato
|
AU641052B2
(en)
|
1990-11-02 |
1993-09-09 |
Aventisub Ii Inc. |
3-amidoindolyl derivatives
|
US5668117A
(en)
|
1991-02-22 |
1997-09-16 |
Shapiro; Howard K. |
Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
|
US20050090553A1
(en)
|
1992-06-30 |
2005-04-28 |
Shapiro Howard K. |
Compositions and method for treatment of chronic inflammatory diseases
|
US6444221B1
(en)
|
1992-06-30 |
2002-09-03 |
Howard K. Shapiro |
Methods of treating chronic inflammatory diseases using carbonyl trapping agents
|
US5472954A
(en)
|
1992-07-14 |
1995-12-05 |
Cyclops H.F. |
Cyclodextrin complexation
|
TW401300B
(en)
|
1992-12-25 |
2000-08-11 |
Senju Pharma Co |
Antiallergic composition for ophthalmic or nasal use
|
US5493027A
(en)
|
1993-01-22 |
1996-02-20 |
Board Of Regents, The University Of Texas System |
Anticonvulsive agents and uses thereof
|
US5767109A
(en)
|
1993-10-20 |
1998-06-16 |
Sanchez; Robert A. |
Complexing urushiols
|
US5576311A
(en)
|
1994-11-30 |
1996-11-19 |
Pharmos Corporation |
Cyclodextrins as suspending agents for pharmaceutical suspensions
|
JP3297969B2
(ja)
|
1994-12-26 |
2002-07-02 |
ライオン株式会社 |
点眼剤
|
US5597823A
(en)
|
1995-01-27 |
1997-01-28 |
Abbott Laboratories |
Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists
|
JP3736916B2
(ja)
|
1996-02-19 |
2006-01-18 |
株式会社サンコンタクトレンズ |
含水性ソフトコンタクトレンズの消毒用組成物とその用途
|
US6107300A
(en)
|
1996-03-27 |
2000-08-22 |
Dupont Pharmaceuticals |
Arylamino fused pyrimidines
|
CA2261916A1
(en)
|
1996-08-01 |
1998-02-12 |
Dowelanco Llc |
4-substituted quinoline derivatives having fungicidal activity
|
WO1998005661A1
(en)
*
|
1996-08-06 |
1998-02-12 |
Pfizer Inc. |
Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic derivatives
|
WO1998050372A1
(de)
|
1997-05-02 |
1998-11-12 |
Schering Aktiengesellschaft |
Substituierte heterocyclen und deren verwendung in arzneimitteln
|
GB2327672A
(en)
|
1997-07-23 |
1999-02-03 |
Merck & Co Inc |
4-(1,2,3,4-Tetrahydro-1,8-naphthyridin-7-yl)butanoyl-glycyl-3(S)-quinolin-3-yl-beta-alanine
|
ATE221886T1
(de)
*
|
1997-09-02 |
2002-08-15 |
Bristol Myers Squibb Pharma Co |
Heterocyclyl-substituierte annellierte pyridine und pyrimidine als antagonisten des corticotropin freisetzenden hormons (crh), verwendbar für die behandlung von cns und stress
|
WO1999046237A1
(en)
|
1998-03-12 |
1999-09-16 |
Novo Nordisk A/S |
Modulators of protein tyrosine phosphatases
|
US6498154B1
(en)
|
1999-05-04 |
2002-12-24 |
Wyeth |
Cyclic regimens using quinazolinone and benzoxazine derivatives
|
US6358948B1
(en)
|
1999-05-04 |
2002-03-19 |
American Home Products Corporation |
Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
|
US6515010B1
(en)
|
1999-11-15 |
2003-02-04 |
Smithkline Beecham Corporation |
Carvedilol methanesulfonate
|
AU1735001A
(en)
|
1999-12-10 |
2001-06-18 |
Senju Pharmaceutical Co., Ltd. |
Cyclodextrin-containing pharmaceutical composition
|
US6569879B2
(en)
|
2000-02-18 |
2003-05-27 |
Merck & Co., Inc. |
Aryloxyacetic acids for diabetes and lipid disorders
|
JP4748289B2
(ja)
|
2000-06-23 |
2011-08-17 |
ライオン株式会社 |
点眼剤、眼科用組成物及び吸着抑制方法
|
FR2827599A1
(fr)
|
2001-07-20 |
2003-01-24 |
Neuro3D |
Composes derives de quinoleine et quinoxaline,preparation et utilisations
|
UA83620C2
(ru)
|
2001-12-05 |
2008-08-11 |
Уайт |
Замещенные бензоксазолы и их аналоги как эстрогенные агенты
|
US20060014786A1
(en)
|
2002-05-17 |
2006-01-19 |
Rajeev Raut |
Opthalmic pharmaceutical compositions and methods for treating ocular inflammation
|
CA2451267A1
(en)
|
2002-12-13 |
2004-06-13 |
Warner-Lambert Company Llc |
Pharmaceutical uses for alpha2delta ligands
|
US20040198828A1
(en)
|
2003-01-17 |
2004-10-07 |
Abelson Mark B. |
Combinational use of long-acting and short-acting anti-histamines for ocular allergies
|
US20040242704A1
(en)
|
2003-03-14 |
2004-12-02 |
University Of Washington, Techtransfer - Invention Licensing |
Stabilized mutant opsin proteins
|
US20060111318A1
(en)
|
2003-04-18 |
2006-05-25 |
Advanced Medicine Research Institute |
Agent for treating eye diseases
|
EP2292239A3
(en)
|
2003-04-18 |
2011-03-30 |
Advanced Medicine Research Institute |
Remedies for diseases to be applied to eye
|
US20040235892A1
(en)
|
2003-05-22 |
2004-11-25 |
Yujia Dai |
Indazole and benzisoxazole kinase inhibitors
|
US7297709B2
(en)
|
2003-05-22 |
2007-11-20 |
Abbott Laboratories |
Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
|
US7083803B2
(en)
|
2003-09-19 |
2006-08-01 |
Advanced Ocular Systems Limited |
Ocular solutions
|
JP2005132834A
(ja)
|
2003-10-09 |
2005-05-26 |
Kyowa Hakko Kogyo Co Ltd |
キノリン誘導体
|
CN1863779B
(zh)
|
2003-10-15 |
2010-05-05 |
宇部兴产株式会社 |
吲唑衍生物
|
RU2006118325A
(ru)
|
2003-10-27 |
2007-12-10 |
Астеллас Фарма Инк. (Jp) |
Производные пиразина и их фармацевтическое применение
|
US20050130906A1
(en)
|
2003-11-20 |
2005-06-16 |
Matier William L. |
Amelioration of macular degeneration and other ophthalmic diseases
|
US20050197292A1
(en)
|
2004-01-30 |
2005-09-08 |
Glennda Smithson |
Compositions and methods for treating T-cell mediated pathological conditions
|
BRPI0507807A
(pt)
|
2004-02-17 |
2007-07-31 |
Harvard College |
gerenciamento de distúrbios oftalmológicos, incluindo degeneração macular
|
US20050234018A1
(en)
|
2004-04-15 |
2005-10-20 |
Allergan, Inc. |
Drug delivery to the back of the eye
|
JP2006008568A
(ja)
|
2004-06-24 |
2006-01-12 |
Cyclochem:Kk |
IgE抗体抑制剤および食品
|
WO2006002473A1
(en)
|
2004-07-02 |
2006-01-12 |
Adelaide Research & Innovation Pty Ltd |
Method of controlling damage mediated by alpha, beta-unsaturated aldehydes
|
FR2875409B1
(fr)
|
2004-09-17 |
2010-05-07 |
Sanofi Aventis |
Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose
|
WO2006049968A1
(en)
|
2004-10-28 |
2006-05-11 |
Merck & Co., Inc. |
Pyrimidine and quinoline potentiators of metabotropic glutamate receptors
|
JPWO2006077821A1
(ja)
|
2005-01-19 |
2008-06-19 |
大日本住友製薬株式会社 |
アルドステロン受容体調節剤としての芳香族スルホン化合物
|
TW200640443A
(en)
|
2005-02-23 |
2006-12-01 |
Alcon Inc |
Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
|
EP1893174A2
(en)
|
2005-05-10 |
2008-03-05 |
Cytophil, Inc. |
Injectable hydrogels and methods of making and using same
|
EP1888548B1
(en)
|
2005-05-26 |
2012-08-22 |
Neuron Systems, Inc |
Quinoline derivative for the treatment of retinal diseases
|
TWI424838B
(zh)
|
2005-12-27 |
2014-02-01 |
Lion Corp |
Composition of soft contact lens and method for inhibiting adsorption
|
US7842312B2
(en)
|
2005-12-29 |
2010-11-30 |
Cordis Corporation |
Polymeric compositions comprising therapeutic agents in crystalline phases, and methods of forming the same
|
US20070297981A1
(en)
|
2006-01-25 |
2007-12-27 |
Ousler George W Iii |
Formulations and methods for treating dry eye
|
US20070203216A1
(en)
*
|
2006-02-14 |
2007-08-30 |
Bjarke Ebert |
Method of treating inflammatory diseases
|
JP4466875B2
(ja)
|
2006-04-05 |
2010-05-26 |
ライオン株式会社 |
ソフトコンタクトレンズ用点眼剤
|
DK2012789T3
(da)
|
2006-04-14 |
2013-12-16 |
Prana Biotechnology Ltd |
Fremgangsmåde til behandling af aldersrelateret makulær degeneration (AMD)
|
JP5194218B2
(ja)
|
2006-06-05 |
2013-05-08 |
株式会社メニコンネクト |
含水性コンタクトレンズの保存方法ならびに該保存方法により保存された含水性コンタクトレンズ
|
JP2009544631A
(ja)
|
2006-07-25 |
2009-12-17 |
エンビボ ファーマシューティカルズ インコーポレイテッド |
キノリン誘導体
|
US7956189B2
(en)
|
2006-08-14 |
2011-06-07 |
Schering Corporation |
Maleate, tosylate, fumarate and oxalate salts of 5-(1-(S)-amino-2-hydroxyethyl)-N-[(2,4-difluorophenyl)-methy]-2-[8-methoxy-2-(triflouromethy)-5-quinoline]-4-oxazolecarboxamide and preparation process therefore
|
WO2008027993A2
(en)
|
2006-08-31 |
2008-03-06 |
Eurand, Inc. |
Drug delivery systems comprising solid solutions of weakly basic drugs
|
US8158609B1
(en)
|
2006-11-02 |
2012-04-17 |
Novartis Ag |
Use of cyclodextrins as an active ingredient for treating dry AMD and solubilizing drusen
|
US20080241256A1
(en)
|
2007-03-30 |
2008-10-02 |
Liisa Kuhn |
Targeted active agent delivery system based on calcium phosphate nanoparticles
|
TW200914437A
(en)
*
|
2007-06-20 |
2009-04-01 |
Ironwood Pharmaceuticals Inc |
FAAH inhibitors
|
CN101889017B
(zh)
|
2007-10-05 |
2013-11-27 |
奥克塞拉有限公司 |
用于治疗疾病的烷氧基化合物
|
WO2009102418A1
(en)
|
2008-02-11 |
2009-08-20 |
University Of Washington |
Methods for the treatment and prevention of age-related retinal dysfunction
|
EP2331534A4
(en)
|
2008-08-12 |
2013-01-16 |
Sirtris Pharmaceuticals Inc |
BENZOXAZOLES, BENZTHIAZOLES AND RELATED ANALOGUES AS MODULATORS OF SIRTUINE
|
EA201100654A1
(ru)
|
2008-10-22 |
2012-01-30 |
Акусела, Инк. |
Соединения для лечения офтальмологических заболеваний и расстройств
|
MX2011004924A
(es)
|
2008-11-11 |
2011-05-30 |
Novartis Ag |
Sales de fingolimod.
|
US20100240624A1
(en)
|
2009-03-17 |
2010-09-23 |
Aciex Therapeutics, Inc. |
Ophthalmic Formulations of Ketotifen and Methods of Use
|
WO2010133672A1
(en)
|
2009-05-20 |
2010-11-25 |
Clanotech Ab |
Derivatives of quinoline-3-carboxylic acid and their medical use
|
MX2011013061A
(es)
|
2009-06-05 |
2012-02-28 |
Aciex Therapeutics Inc |
Formulaciones oftalmicas de fluticasona y metodos de uso.
|
WO2010148351A1
(en)
*
|
2009-06-18 |
2010-12-23 |
Cylene Pharmaceuticals, Inc. |
Rhodanines and related heterocycles as kinase inhibitors
|
WO2011008202A1
(en)
|
2009-07-15 |
2011-01-20 |
Vanderbilt University |
Isoketal scavengers and mitigation of disorders involving oxidative injury
|
TWI492769B
(zh)
|
2009-09-23 |
2015-07-21 |
Alcon Res Ltd |
可注射的水性眼用組成物及其使用之方法
|
EP2509596B1
(en)
|
2009-12-08 |
2019-08-28 |
Case Western Reserve University |
Gamma aminoacids for treating ocular disorders
|
JP5885670B2
(ja)
|
2009-12-11 |
2016-03-15 |
アルデイラ セラピューティクス, インコーポレイテッド |
黄斑変性の処置のための組成物および方法
|
WO2011078204A1
(ja)
|
2009-12-24 |
2011-06-30 |
浜理薬品工業株式会社 |
高脂血症の予防または治療剤、および抗疲労剤
|
PE20121699A1
(es)
|
2010-02-26 |
2012-12-22 |
Xenon Pharmaceuticals Inc |
Composiciones farmaceuticas del compuesto espiro-oxindol para administracion topica
|
WO2011116066A1
(en)
|
2010-03-17 |
2011-09-22 |
Concert Pharmaceuticals, Inc. |
Derivatives of dimethylcurcumin
|
WO2012030938A1
(en)
|
2010-09-01 |
2012-03-08 |
Arena Pharmaceuticals, Inc. |
Salts of lorcaserin with optically active acids
|
WO2012097173A2
(en)
|
2011-01-12 |
2012-07-19 |
Ventirx Pharmaceuticals, Inc. |
Substituted benzoazepines as toll-like receptor modulators
|
WO2012100142A2
(en)
|
2011-01-20 |
2012-07-26 |
Cornell University |
Treatments for retinal disorders
|
CN103442735B
(zh)
|
2011-01-31 |
2016-11-09 |
特米拉公司 |
用于减轻技术领域中所不希望的医学状况的有效要素
|
TWI544922B
(zh)
|
2011-05-19 |
2016-08-11 |
愛爾康研究有限公司 |
高濃度歐羅派特錠(olopatadine)眼用組成物
|
CN104159594A
(zh)
|
2011-10-13 |
2014-11-19 |
托马斯·盖德克 |
用于皮肤病治疗的凯莫瑞c15肽的局部制剂
|
US20130190500A1
(en)
|
2011-12-12 |
2013-07-25 |
Neuron Systems, Inc. |
Process to prepare 6-chloro-3-amino-2-(2-hydroxypropyl)-1-azanaphthalene
|
US20130165419A1
(en)
|
2011-12-21 |
2013-06-27 |
Insite Vision Incorporated |
Combination anti-inflammatory ophthalmic compositions
|
JP6545618B2
(ja)
|
2012-08-01 |
2019-07-17 |
ルイス アンド クラーク ファーマスーティカルズ,インコーポレイテッドLewis and Clark Pharmaceuticals,Inc. |
A2aアゴニストとしてのn−アルキル2−(二置換)アルキニルアデノシン−5’−ウロンアミド
|
CN104884049A
(zh)
|
2012-11-08 |
2015-09-02 |
克莱尔塞德生物医学股份有限公司 |
用于在人类受试者中治疗眼部疾病的方法和装置
|
KR20150118106A
(ko)
|
2012-12-20 |
2015-10-21 |
알데이라 테라퓨틱스, 아이엔씨. |
페리-카르비놀
|
KR102055937B1
(ko)
|
2013-01-23 |
2019-12-13 |
셈누르 파마슈티칼스, 인코포레이티드 |
불용성 코르티코스테로이드 및 수용성 코르티코스테로이드를 포함하는 약학적 제형
|
EP2948149A4
(en)
|
2013-01-23 |
2016-12-14 |
Aldeyra Therapeutics Inc |
BY TOXIC ALDEHYDIC DISEASES AND TREATMENT
|
CN105228989A
(zh)
|
2013-01-25 |
2016-01-06 |
奥尔德拉医疗公司 |
黄斑变性治疗中的新颖捕获剂
|
TWI643853B
(zh)
|
2013-02-27 |
2018-12-11 |
阿爾米雷爾有限公司 |
同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
|
US9713330B1
(en)
|
2013-03-15 |
2017-07-25 |
Deuteria Agrochemicals, Llc |
Deuterium-enriched aldehydes
|
WO2015002893A1
(en)
|
2013-07-02 |
2015-01-08 |
The Trustees Of Columbia University In The City Of New York |
Clearance of bioactive lipids from membrane structures by cyclodextrins
|
US10272106B2
(en)
|
2014-06-04 |
2019-04-30 |
Case Western Reserve University |
Compositions and methods of treating diabetic retinopathy
|
JP6634034B2
(ja)
|
2014-06-25 |
2020-01-22 |
シネルジア・バイオ・サイエンシーズ・プライベイト・リミテッドSynergia Bio Sciences Private Limited |
医薬水中油型ナノエマルジョン
|
BR112016029338A2
(pt)
|
2014-07-29 |
2017-08-22 |
Therapeuticsmd Inc |
creme transdérmico
|
NO2721710T3
(es)
|
2014-08-21 |
2018-03-31 |
|
|
EP3628640B1
(en)
|
2014-09-02 |
2023-08-09 |
Hub Therapeutics |
Methods of making a deuterated or a non-deuterated molecule and pharmaceutical formulations for treatment
|
TW201628622A
(zh)
|
2014-11-17 |
2016-08-16 |
製藥公司 |
Tlr抑制劑與布魯頓氏(bruton's)酪胺酸激酶抑制劑之組合
|
WO2016085939A2
(en)
|
2014-11-24 |
2016-06-02 |
Case Western Reserve University |
Compounds and methods of treating ocular disorders
|
TWI736531B
(zh)
|
2015-04-15 |
2021-08-21 |
英屬開曼群島商百濟神州有限公司 |
B-raf 激酶抑制劑的馬來酸鹽、其結晶形式、製備方法及用途
|
KR102664994B1
(ko)
|
2015-08-21 |
2024-05-13 |
알데이라 테라퓨틱스, 아이엔씨. |
중수소화 화합물 및 이의 용도
|
AU2016311163A1
(en)
*
|
2015-08-21 |
2018-04-05 |
Aldeyra Therapeutics, Inc. |
Aldehyde conjugates and uses thereof
|
BR112018069533A2
(pt)
|
2016-02-28 |
2019-04-16 |
Aldeyra Therapeutics, Inc. |
tratamento de condições alérgicas oculares com ciclodextrinas
|
CN109152774A
(zh)
|
2016-05-09 |
2019-01-04 |
奥尔德拉医疗公司 |
眼部炎性病症和疾病的组合治疗
|
WO2017214201A1
(en)
|
2016-06-06 |
2017-12-14 |
Thesan Pharmaceuticals, Inc. |
Formulations for substituted 3-pyrrolidines, compositions containing, and uses of, same
|
WO2018039197A1
(en)
|
2016-08-22 |
2018-03-01 |
Aldeyra Therapeutics, Inc. |
Aldehyde trapping compounds and methods of use thereof
|
WO2018039192A1
(en)
|
2016-08-22 |
2018-03-01 |
Aldeyra Therapeutics, Inc. |
Aldehyde trapping compounds and uses thereof
|
MX2019003623A
(es)
|
2016-09-28 |
2019-09-23 |
Medicon Pharmaceuticals Inc |
Composiciones y metodos para el tratamiento de afecciones oftalmicas.
|
JP7017563B2
(ja)
|
2016-10-05 |
2022-02-08 |
ミトブリッジ,インコーポレーテッド |
Pparアゴニスト化合物の結晶性および塩形態
|
JP2020511461A
(ja)
|
2017-03-16 |
2020-04-16 |
アルデイラ セラピューティクス, インコーポレイテッド |
多形化合物およびその使用
|
MX2020003425A
(es)
|
2017-10-10 |
2020-07-29 |
Aldeyra Therapeutics Inc |
Tratamiento de trastornos inflamatorios.
|
WO2020018498A1
(en)
|
2018-07-16 |
2020-01-23 |
Aldeyra Therapeutics, Inc. |
Cyclodextrin formulations
|
US20200038392A1
(en)
|
2018-08-03 |
2020-02-06 |
Aldeyra Therapeutics, Inc. |
Topical compositions and methods of preparation and use
|
US12006298B2
(en)
|
2018-08-06 |
2024-06-11 |
Aldeyra Therapeutics, Inc. |
Polymorphic compounds and uses thereof
|
CN115869258A
(zh)
|
2018-09-25 |
2023-03-31 |
奥尔德拉医疗公司 |
用于治疗干眼病的调配物
|
JP2022503994A
(ja)
|
2018-10-02 |
2022-01-12 |
アルデイラ セラピューティクス, インコーポレイテッド |
コンタクトレンズ溶液およびキット
|
WO2020118045A1
(en)
|
2018-12-05 |
2020-06-11 |
Aldeyra Therapeutics, Inc. |
Injectable formulations
|
JP2022526917A
(ja)
|
2019-03-26 |
2022-05-27 |
アルデイラ セラピューティクス, インコーポレイテッド |
眼科用製剤およびその使用
|
WO2020223717A1
(en)
|
2019-05-02 |
2020-11-05 |
Aldeyra Therapeutics, Inc. |
Process for preparation of aldehyde scavenger and intermediates
|
US20230131929A1
(en)
|
2020-03-24 |
2023-04-27 |
Aldeyra Therapeutics, Inc. |
Quinoline compounds for treating respiratory disorders and viral infections
|
JP2023522000A
(ja)
|
2020-04-13 |
2023-05-26 |
アルデイラ セラピューティクス, インコーポレイテッド |
肺、肝臓、および腎臓の疾患、障害、または状態を処置するためのキノリン化合物
|
CN115697336A
(zh)
|
2020-05-13 |
2023-02-03 |
奥尔德拉医疗公司 |
药物制剂及其用途
|
US20230228744A1
(en)
|
2020-06-04 |
2023-07-20 |
Aldeyra Therapeutics, Inc. |
Dry eye disease biomarkers and their use for treatment
|
WO2022150580A1
(en)
|
2021-01-07 |
2022-07-14 |
Aldeyra Therapeutics, Inc. |
Treatment of dry eye disease
|
US20220211691A1
(en)
|
2021-01-07 |
2022-07-07 |
Aldeyra Therapeutics, Inc. |
Treatment of dry eye disease
|